[ad_1]
A clinical trial volunteer in Brazil of AstraZeneca / Oxford from the Covid-19 vaccine he died, but the trial continues because the deceased person never took a dose of the vaccine, he was part of the placebo group.
The news was published by Reuters, picked up by the Bloomberg agency, citing the Brazilian health authority Anvisa and the federal university of Sao Paulo, which helps coordinate phase 3 of the trial in the South American country. The Brazilian health authority Anvisa has specified that the trial will continue. However, according to Bloomberg reports, the victim would never have received a dose of the vaccine.
The evaluations carried out “did not raise concerns about the continuation
Current Study ‘for the vaccine trial. This was stated by the multinational AstraZeneca, which is developing the anti-Covid vaccine in collaboration with the University of Oxford and the Irbm of Pomezia, in reference to the news – later denied – of the death of a volunteer involved in the experiment.
Final Phase 3 testing of this vaccine candidate is ongoing.
Also according to reports from the Brazilian newspaper Or Balloon, citing anonymous sources, the volunteer the test vaccine was not administered but a placebo: In a statement, Oxford disclosed that After careful consideration, “there were no concerns about the safety of the clinical trial,” writes Reuters. Anvisa did not provide further details to protect confidentiality, while AstraZeneca (whose shares fell 1.7%) declined to comment.
The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, said the volunteer was Brazilian, but did not reveal from where. The federal government plans to buy the vaccine from the UK and manufacture it at its FioCruz biomedical research center in Rio de Janeiro, while a competitor vaccine from China’s Sinovac Biotech Ltd SVA.O is being tested by the state research center of San Instituto. Paolo Butantan.
Last updated: Wednesday 21 October 2020, 23:42
© REPRODUCTION RESERVED
